Rgenta Therapeutics has received FDA approval for its new drug, RGT-61159, to treat various cancers by targeting RNA splicing to inhibit MYB protein production.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Rgenta Therapeutics has received FDA approval for its new drug, RGT-61159, to treat various cancers by targeting RNA splicing to inhibit MYB protein production.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.